ClinicalTrials.gg
RecruitingNCT04433052Updated Jun 12, 2023

Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

An interventional study of personalised prevention program (PPP) in Coronary Heart Disease, sponsored by Tampere University. Recruiting at 26 sites in 6 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by Tampere University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12,000
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Coronary Disease with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Disease · Poland.

Planned enrollment
5th of 25
12,000 · median 1,257
Started
2023
with 1 other
No phase
8 of 32
2 open now
Registered
28th of 32
by date

Among the 32 studies in Coronary Disease with a site in Poland, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 28th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

5 of the 32 studies in Coronary Disease with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Coronary Disease with a site in Poland, or all of them as a file.
02

Study summary

Prospective clinical study with two parts:

PART A: a prospective biomarker-based risk screening study in coronary heart disease (CHD) subjects PART B: a nested randomized clinical trial (RCT) in an enriched subpopulation of high-risk stable CHD subjects

PART A: 12 000 subjects with stable CHD

PART B: 2000 subjects with high risk of CV events will be randomized to usual care (UC) or personalised prevention program (PPP) i.e. 1000 subjects per arm.

Study purpose is to assess the clinical value and cost-effectiveness of a personalised prevention program (PPP) in high-risk, stable coronary heart disease (CHD) subjects and to prospectively validate risk screening biomarkers

Read the detailed description

Primary Objectives:

PART A:

  • To prospectively validate biomarkers in risk stratification among stable CHD subjects, i.e. evaluation of the biomarker performance in accurately predicting CV events including CV death, nonfatal MI, HF events
  • To identify high-risk CHD subjects for the subsequent RCT, i.e. 15-20% of the screened patient population at the highest risk

PART B

  • To demonstrate whether a personalised prevention (PPP) strategy in high-risk CHD subjects results in a decreased risk of cardiovascular (CV) events (CV death, nonfatal myocardial infarction (MI) or heart failure (HF) events) as compared to the local usual care (UC)

Secondary Objectives:

  • To evaluate the difference between the PPP arm to the UC arm as listed in section outcomes.
  • To evaluate the health economic value of the PPP
  • To prospectively study associations (in all enrolled subjects) between separate biomarkers (CERT2, hs-troponin, proBNP, Cystatin C) or their score (CoroPredict)

In addition to the above-listed primary and secondary objectives of the study, the following analysis will be carried out based on the data to be collected during the trial:

  • Effect of personalised prevention on behavioural change.
  • Effect of behavioural change on CV outcomes and blood pressure.
  • Identification of key components and risk factors affecting effectiveness of the PPP.
  • Inter-relationship between nutrition and exercise will be evaluated. Nutrition parameters will be based on questionnaires and biomarkers (Trimethylamine N-oxide (TMAO), Trimethyllysine (TML), carnitines and their metabolites).
  • Effect of the use of the CoroPrevention Tool Suite (EXPERT tool) on the agreement between exercise prescriptions generated by cardiovascular nurses to subjects with CVD, and the ESC guideline-directed exercise prescriptions
  • Effect of greater adherence to EXPERT tool-driven exercise prescriptions by clinicians and subjects, on CVD risk, physical fitness, and prognosis (hospitalisations, adverse events, mortality) in subjects with CVD.
  • Effect of the use of the EXPERT tool-driven medication decision support system on the agreement between medication prescriptions generated by cardiovascular nurses to subjects with CVD, and the ESC guideline-directed medication prescriptions
  • Effect of better adherence by both clinicians and subjects to ESC guideline prescriptions, driven by the medication decision support system within the EXPERT tool, on CVD risk and prognosis (hospitalisations, adverse events, mortality) in subjects with CVD.
  • Investigation of the user experience and user acceptance of the CoroPrevention Tool Suite.
03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • Prevention
  • Coronary Heart Disease
  • Biomarkers
  • Lifestyle
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligible study subjects must meet all of the following inclusion criteria:

  1. form signed by the study subjects.
  2. Male or female aged 30 to 80 years on the day of enrolment.
  3. > 50% stenosis in one or more major coronary arteries on angiography or computerised tomography (CT) performed within the preceding one year (from enrolment visit).

or Myocardial infarction (type I, II) during the preceding year.

Eligible study subjects must not meet any of the following exclusion criteria:

  1. Hospitalisation for acute coronary syndrome, myocardial infarction, stroke, coronary revascularisation or acute heart failure within the preceding one month (30 days). These subjects can be enrolled after a one-month stabilisation period, which begins from the time of the event.
  2. Subjects with class III-IV heart failure i.e. marked limitation in activity due to symptoms, comfortable only at rest.
  3. Uncontrolled arrhythmias such as ventricular tachycardias.
  4. Subjects undergoing dialysis due to severe renal disease.
  5. Diseases that severely disable exercising (per investigator's judgement), such as rheumatoid arthritis, neurological or orthopaedic diseases.
  6. Known aplastic or haemolytic anaemia.
  7. Concomitant non-coronary disease, such as that limits to less than three years.
  8. Concurrent participation in another interventional study.
  9. Subjects not able and/or willing to attend all scheduled visits and comply with all study procedures and use a smartphone application.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12,000 participants (estimated)

Study arms

  • Experimental
    Personalised prevention program (PPP)

    Participants will be invited to return to the study site six times over a three year period to receive lifestyle coaching and exercise prescriptions. Eupropean Society of Cardiology/European Association of Preventive Cardiology (ESC/EAPC) -designed lifestyle counselling will be partially delivered by novel smartphone applications. Participants will also receive pharmaceutical treatment according to the ESC guideline for chronic coronary syndromes.

    Behavioral: personalised prevention program (PPP)

  • No intervention
    Usual care (UC)

    Participants will be referred back to usual care provided by their treating physicians. It is anticipated that physicians will treat these participants according to local usual medical practices. Patients randomized to UC group will not receive any treatment recommendations nor restrictions by the study investigators or nurses. Randomized UC patients are invited to site visits twice over a three year period.

Interventions

  • Behavioralpersonalised prevention program (PPP)

    Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.

06

What researchers measure

Primary outcomes

  1. To demonstrate whether a PPP strategy in high-risk CHD subjects results in a decreased risk of CV events (CV death, nonfatal MI or HF events) compared to the UC

    • The time from randomisation to the occurrence of the first CV event included in the composite endpoint of the study (CV death, nonfatal MI, HF events) over 3 years follow-up.

    Time frame: 3 years follow-up

Secondary outcomes

  1. To evaluate the difference between PPP arm to the UC arm in

    o The times from randomisation to the occurrence of the specific items included in the composite endpoint (CV death, nonfatal MI, HF event) over 3 years follow-up

    Time frame: 3 years follow-up

  2. To evaluate the difference between PPP arm to the UC arm in

    o The times from randomisation to the occurrence of secondary CV events (unstable angina, stroke and coronary revascularisations excluding those elective revascularisations that have been planned prior to randomisation)

    Time frame: 3 years follow-up

  3. To evaluate the difference between PPP arm to the UC arm in

    o Treatment adherence; measured by compliance laboratory assessments and in the PPP group, also with activity reports

    Time frame: 3 years follow-up

  4. To evaluate the difference between PPP arm to the UC arm in

    All-cause mortality

    Time frame: 3 years follow-up

  5. To evaluate the difference between PPP arm to the UC arm in

    Incidence of additional clinical endpoints: diabetes mellitus type 2 (DM2), chronic kidney disease (CKD), peripheral artery disease (PAD) and hypertension

    Time frame: 3 years follow-up

  6. To evaluate the health economic value of the PPP

    o A cost-effectiveness analysis of PPP versus UC will be undertaken, based on evidence from the randomised clinical trial (RCT) portion of the study, using within-trial analysis and long-term cost-effectiveness modelling for the six countries participating in the CoroPrevention trial: Finland, Poland, Greece, Portugal, Italy, and Germany.

    Time frame: 3 years follow-up

  7. • To prospectively study associations (in all enrolled subjects) between separate risk biomarkers (CERT2, hs-troponin , proBNP, Cystatin C) or their score (CoroPredict) and

    * Primary composite CV event (CV death, MI, HF events) * Specific CV events (CV death, nonfatal MI, HF events) separately * Specific secondary CV events (unstable angina, stroke, coronary revascularisations) * Incidence of DM2, CKD, PAD and hypertension

    Time frame: 3 years follow-up

07

Study locations

3 of 26 sites recruiting
  • Helsinki University Hospital
    Helsinki, Finland
    Recruiting
  • Mehiläinen
    Helsinki, Finland
    Recruiting
  • Kuopio University Hospital
    Kuopio, Finland
    Not yet recruiting
  • Oulu University Hospital
    Oulu, Finland
    Recruiting
  • Klinik am See
    Berlin, Germany
    Not yet recruiting
    • Heinz Völler, MD, PhD · Contact
  • CCV-MVZ
    Frankfurt, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Heidelberg University
    Mannheim, Germany
    Not yet recruiting
    • Winfried März, MD, PhD · Contact
  • Technise Universität Munchen
    München, Germany
    Not yet recruiting
    • Martin Halle, MD, PhD · Contact
  • Herzklinik Ulm
    Ulm, Germany
    Not yet recruiting
    • Ralf Birkemeyer, MD, PhD · Contact
  • Hellenic Red Cross Hospital
    Athens, Greece
    Not yet recruiting
    • Nikolaos Bourmpoulis, MD, PhD · Contact
  • Konstantopoulio Hospital
    Athens, Greece
    Not yet recruiting
    • Patsilinakos Sotirios, MD, PhD · Contact
  • Sismanoglion Hospital
    Athens, Greece
    Not yet recruiting
    • Dimitrios Sionis, MD, PhD · Contact
  • The Biomedical Research Foundation of the Academy Athens
    Athens, Greece
    Not yet recruiting
  • University Hospital Genova
    Genova, Italy
    Not yet recruiting
  • Multi Medica, Care and Research Institute
    Milan, Italy
    Not yet recruiting
    • Roberto FE Pedretti, MD, PhD · Contact
  • Casilino Hospital Rome
    Rome, Italy
    Not yet recruiting
    • Leonardo Calo, MD, PhD · Contact
  • University Hospital Turin
    Turin, Italy
    Not yet recruiting
  • University of Bialystok
    Białystok, Poland
    Not yet recruiting
    • Karol Kaminski, MD, PhD · Contact
  • Medical University of Silesia
    Katowice, Poland
    Not yet recruiting
  • Jagellonian University Medical College
    Kraków, Poland
    Not yet recruiting
  • University of Lublin
    Lublin, Poland
    Not yet recruiting
    • Andrzej Wysokinski, MD, PhD · Contact
  • Nicolaus Copernicus University
    Toruniak, Poland
    Not yet recruiting
    • Aldona Kubica, MD, PhD · Contact
  • National Institute of Cardiology
    Warsaw, Poland
    Not yet recruiting
    • Rafal Dabrowski, MD, PhD · Contact
  • Hospital de Santa Cruz-CHLO
    Carnaxide, Portugal
    Not yet recruiting
    • Miguel Mendes, MD, PhD · Contact
  • Hospital do Espirito Santo
    Lisbon, Portugal
    Not yet recruiting
    • Lino Patricio, MD, PhD · Contact
  • Hospital Santa Maria-CHULN/FMUL
    Lisbon, Portugal
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — EU open access policy

Time frame: opens 2 years after last study patient visit, open for 18 years until IPD deletion

Access criteria: Steering Committee decision, application needed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 46 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 16, 2020
StartActual
Feb 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04433052
Lead sponsor
Tampere University
Responsible party
Reijo Laaksonen (Project Director, Tampere University) — Principal investigator
First posted
Jun 16, 2020
Start date
Feb 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 12, 2023

Study contacts

Hanna Marttila, MSc
Contact
hanna.marttila@tuni.fi
+358407240771
Reijo Laaksonen, MD, PhD
study director · Tampere University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion